BOSTON, MA — October 6, 2025 — Leads & Copy — BPGbio, Inc. has appointed Brian Berman, M.D., Ph.D., a senior Scientific Advisory Board member, as Interim Chief Medical Officer (CMO). Dr. Berman succeeds Vijay Modur, M.D., Ph.D.
Dr. Berman will oversee all clinical development and medical affairs activities, focusing on progressing the company’s lead program, BPM31510, which is in planning stages for a registrational trial for Primary CoQ10 Deficiency (PCQD) and in Phase 2b trials for glioblastoma multiforme (GBM). He will also guide the company’s expanding portfolio in oncology and other rare diseases.
Dr. Berman previously spearheaded the initiation and execution of the Phase 2b trial for GBM in 2022 while serving as Acting CMO. He also directed clinical studies evaluating BPM31510 in treating in situ cutaneous squamous cell carcinoma (SCC).
Niven R. Narain, Ph.D., President and CEO of BPGbio, expressed gratitude to Dr. Vijay Modur for his contributions and leadership as Chief Medical Officer, noting that he will remain available to advise the company.
Dr. Berman serves as Co-Director of the Center for Clinical and Cosmetic Research in Aventura, FL. He is also Professor Emeritus at The University of Miami Miller School of Medicine and has held leadership positions in several dermatological associations.
Contact:media@bpgbio.com
Source: BPGbio
